Home
Healthcare
Summary
Novavax receives a Hold rating, reflecting neutral fundamentals despite a Q1 earnings beat and strong recent price momentum.
NVAX's upside hinges on executing strategic partnerships, notably with Pfizer, and advancing its vaccine pipeline amid sector tailwinds from infectious disease outbreaks.
Profitability remains elusive, with negative equity and choppy cash flow; consensus expects no positive EPS until at least 2028.
Valuation implies nearly 40% upside to Wall Street's $14.11 target, but technicals and seasonal demand volatility temper conviction in a sustained rally.
spawns/E+ via Getty Images
A Vaccine Company With a Q1 Earnings Beat
After it beat Q1 earnings estimates by an impressive $0.31, Novavax ( NVAX ) gets initial coverage from me today in the biotech/pharma sector, whose profile describes it
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the…